心血管疾病中的内皮间质转化:分子机制与临床展望
内皮间质转化(EndMT)是内皮细胞获得间质样表型的过程,在胚胎心脏发育中形成心内膜垫并最终发育为心脏瓣膜。近期通过小鼠谱系追踪和单细胞RNA测序等技术,在多种成人心血管疾病中观察到EndMT。本综述重点讨论EndMT在成人心血管疾病中的功能作用,以动脉粥样硬化和瓣膜病为例,并指出缺乏分子层面标准化定义及人类机制证据等挑战。
要点
- EndMT在移植血管病变、肺动脉高压、静脉桥重塑、动脉粥样硬化和瓣膜病中证据最强。
- TGF-β通路是EndMT的主要驱动因素,但并非唯一信号机制。
- 大型动物研究已抑制EndMT并获阳性结果,为首次人体临床抑制铺路。
核心结论
- EndMT在多种成人心血管疾病中发挥功能作用,以动脉粥样硬化和瓣膜病为范例。
- 大型动物研究抑制EndMT的阳性结果支持其作为治疗策略进入首次人体临床研究。
研究设计与样本
- 综述文章,总结EndMT在心血管疾病中的分子机制与临床前景。
- 文中引用小鼠谱系追踪和单细胞RNA测序等研究工具的证据。
主要发现
- EndMT在胚胎心脏发育中形成心内膜垫并最终发育为心脏瓣膜。
- 成人中EndMT证据最强的疾病包括移植血管病变、肺动脉高压、静脉桥重塑、动脉粥样硬化和瓣膜病。
- TGF-β通路是EndMT的主要驱动因素,但非唯一信号机制。
- 大型动物研究已抑制瓣膜病和静脉桥重塑中的EndMT并获阳性结果。
关键数值与推荐
- 缺乏EndMT在分子层面的标准化定义。
- 尚需在人类中证明EndMT机制性参与心血管疾病病理生理。
临床怎么用
- 关注EndMT作为心血管疾病潜在治疗靶点,尤其瓣膜病和静脉桥重塑。
- 临床转化前需解决EndMT分子定义标准化和人类机制验证问题。
局限性
- 缺乏EndMT分子层面的标准化定义。
- 人类中EndMT机制性参与疾病的证据尚未获得。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Endothelial to mesenchymal transition (EndMT) is a process whereby endothelial cells transition to adopt a mesenchymal-like fate, e.g. to become smooth muscle cells, osteoblasts, fibroblasts, or chondrocytes. In embryonic heart development, the importance of EndMT was established several decades ago, with ECs undergoing EndMT to give rise to the endocardial cushions that ultimately develop into the cardiac valves. More recently, EndMT has been observed in various adult cardiovascular diseases. This has been established through the application of state-of-the-art research tools, including cell lineage tracing in mice and single cell RNA sequencing, which have allowed in depth profiling of endothelial cells that have undergone transition to a mesenchymal-like state. As with any emerging field, certain challenges have arisen, such as the lack of a standardized definition of what constitutes EndMT at a molecular level and obtaining proof in humans that EndMT is mechanistically involved in the pathophysiology of cardiovascular diseases. The greatest evidence for the presence of cells undergoing EndMT in the adult exists for transplant vasculopathy, pulmonary arterial hypertension, vein graft remodeling, atherosclerosis, and valvular heart disease. The transforming growth factor beta pathway is the major driver, but this is not the exclusive signalling mechanism governing this complex process. Translational large animal studies have already been undertaken to inhibit EndMT in both valvular heart disease and vein graft remodeling, with positive results. These studies pave the way towards first-in-human clinical inhibition of EndMT as a therapeutic strategy. Here we review this exciting field, with particular emphasis on the functional role of EndMT in adult cardiovascular diseases using atherosclerosis and valvular disease as exemplars.
引用
- Hall IF, Aikawa E, Sluimer J, et al. Endothelial to mesenchymal transition in cardiovascular diseases: molecular insights and clinical perspectives. Eur Heart J. 2026. PMID: 41128016. doi:10.1093/eurheartj/ehaf670
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。